Artemisinin Combination Therapy (ACT) Market Top Players, Segments & Regional Trends By 2034

Straits Research released its highly anticipated report,“Global Artemisinin Combination Therapy Market Size & Outlook, 2026-2034”. According to the study, the market size is valued at USD 680.15 million in 2025 and is projected to expand to USD 1394.93 million by 2034, registering a compound annual growth rate (CAGR) of 8.35%.

Market Dynamics

The global artemisinin combination therapy (ACT) market is experiencing strong growth, primarily driven by the increasing prevalence of malaria in tropical and subtropical regions and the widespread adoption of artemisinin-based combination therapies (ACTs) as the standard treatment recommended by the World Health Organization (WHO). Rising government-supported malaria elimination programs, coupled with expanded access to affordable ACTs through public-private partnerships and global health organizations, are further accelerating market expansion.

However, the market faces restraints due to supply chain vulnerabilities and limited cold chain infrastructure in malaria-endemic regions, which affects the timely distribution and stability of ACT formulations. Additionally, fluctuating raw material availability from Artemisia annua cultivation poses challenges to consistent drug supply. On the other hand, several opportunities exist in the development of fixed-dose combinations that enhance treatment compliance, bioavailability, and patient outcomes. Increasing investments in pediatric formulations and collaborations for localized manufacturing in Africa and Asia are also expected to create new growth avenues for the global artemisinin combination therapy market.

Market Highlights

• Type: The artemether + lumefantrine segment held the highest market share in 2025, with a revenue share of 38.23%.
• Distribution Channel: The hospital pharmacies segment dominated the market with a revenue share of 48.52%.
• Regional Insights: North America dominated the market with a 40.17% share, driven by the increasing adoption of advanced malaria treatment protocols and the presence of strong pharmaceutical distribution networks ensuring efficient availability of artemisinin-based therapies.